Vita Mobile Systems (VMSI) racked up an impressive day yesterday up 74% on the day. There was also a big blip in message board activity as measured on Investors Hub ranking in in the number […]
Vita Mobile Systems (VMSI) is up 67% today at the time of this article fueled by the news that “VITA develops artificial intelligence to drive traffic and boost propagation of content.” What they are in […]
Binding deal with software giant Oracle Flagship product NotifiCRM set to disrupt the $36 billion dollar CRM sector Silicon Review just named nFüsz as one of the 50 Fastest Growing Companies of 2017 Juice Plus’ […]
Where there is Smoke there is Fire Current Financials Due in 2018 Dual Listing Coming with Financials Extremely Large Naked Short Position Value Play Surgery Center Update Possible Licensing Strategy with Oral Insulin Eastgate Biotech […]
Shares of DSG Global Inc. today closed at $0.0043 +0.002 (+86.96%) on 26,096,564 shares traded, nearly 2.5x its average 30 day volume. Investor forums are buzzing, as shareholders are hoping for big things from the […]
Dear Shareholder: We have had a lot of developments since our last Shareholder update. We know many of you have been asking for updates and we are excited to share the most recent news. We […]
Recent research suggests 530% revenue growth potential Digital rights management space to grow to $2.5 billion by 2025 Positioned near 52 week low…great entry point based on industry’s future Has executed exclusive contracts with 6 […]
The recent news reports of a series of successful, major cyber attacks specifically targeting Equifax, Deloitte and HBO, and the successful global cyber attacks earlier this year, have resulted in almost incalculable damage. However, collectively, […]
Gold Mining USA, Inc. has changed its primary line of business in connection with its acquisition of VITA Mobile Systems – an app company that focuses on digital imaging and technology in mobile devices. Its […]
PharmaCyte Biotech (PMCB) had a shareholder call to address the developments with their pancreatic cancer and diabetes trials. Most of the call was spent recapping the challenges that they faced in the pathway to regulatory […]
PSInvestor.com